Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-02-13 Major Shareholding Noti…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2018-02-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-13 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 22, 2017, reporting a change in company officers: the resignation of the Principal Accounting Officer and the appointment of a new Principal Accounting Officer. The content focuses on management changes and does not contain financial statements or detailed financial data. This matches the description of Board/Management Information filings, which announce changes in the company's board or senior management. The document length is short (2909 characters), and it is not an announcement of a report publication but a direct report of management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2017-12-28 English
Regulatory Filings 2017
Regulatory Filings
2017-12-20 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to a comment letter from the SEC staff regarding the company's previously filed Forms 10-Q for quarterly periods ended March 31, June 30, and September 30, 2017. The letter specifically addresses corrections to officer certifications included in those filings. The document does not contain actual financial data or the full 10-Q reports themselves, but rather is a regulatory correspondence related to those filings. It is short (2762 characters) and serves as a response to a regulatory comment, fitting the criteria for a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or any other category. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-12-15 English
10-Q/A
Interim / Quarterly Report Q3 2017
2017-12-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.